default author photo

Zhongwu Li

Peking University - Key Laboratory of Carcinogenesis and Translational Research

No. 38 Xueyuan Road

Haidian District

Beijing, Beijing 100871

China

SCHOLARLY PAPERS

1

DOWNLOADS

182

TOTAL CITATIONS

2

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Safety, Efficacy and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial

Number of pages: 139 Posted: 26 Nov 2019
Ming Lu, Panpan Zhang, Yanqiao Zhang, Zhongwu Li, Jifang Gong, Jie Li, Jian Li, Yan Li, Xiaotian Zhang, Zhihao Lu, Xicheng Wang, Jun Zhou, Zhi Peng, Weifeng Wang, Hui Feng, Hai Wu, Sheng Yao and Lin Shen
Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Harbin Medical University - Cancer Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, OrigiMed, Inc., Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD, Shanghai Junshi Biosciences Co., LTD and Peking University - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)
Downloads 182 (418,025)
Citation 2

Abstract:

Loading...

Neuroendocrine neoplasm, NET, NEC, PD-1,toripalimab